January 2015 | Oncology Live®

January 26, 2015

The toolkit for attacking many tumor types is well stocked, and the prospects for continued progress are brighter than ever.

January 20, 2015

As varying immunotherapy options become available for different types of cancers, researchers will have to take the next steps in clinical studies and in practice before the growing excitement over emerging agents can truly be translated into beneficial new therapies for patients.

January 19, 2015

OncologyLive asked experts in lymphoma, chronic myeloid leukemia, breast cancer, and non–small cell lung cancer to discuss the impact that the first targeted agents have had on these malignancies and the prospects for new therapeutic approaches.

January 14, 2015

Agents that target components of the programmed death-1 (PD-1) pathway are poised to make an impact on the treatment of patients with hematologic malignancies, particularly Hodgkin lymphoma (HL).

January 12, 2015

The FDA's calendar for making decisions on new oncology drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.

January 08, 2015

Hagop M. Kantarjian, MD, has built the nation's largest clinical leukemia practice, in part to ensure that leukemia studies are completed efficiently and in a timely manner.

January 07, 2015

For more than two decades, Kenneth Offit, MD, MPH, has been researching the molecular genetic factors that increase cancer risk, notably concerning germline BRCA mutations in breast and ovarian cancer, with a focus on potential preventive surgical remedies and screening programs for women at hereditary risk.

January 06, 2015

There has been considerable discussion and debate within the gynecologic oncology community for more than two decades regarding a role for second-look surgery (open or laparoscopic) in the management of advanced ovarian cancer.

January 06, 2015

Circulating tumor cell (CTC) enumeration is a strong prognostic factor in metastatic breast cancer (MBC) and predicts treatment failure.

January 05, 2015

A lung cancer researcher who has served on the editorial boards of major medical journals, Howard L. "Jack" West, MD, has made communicating with oncology specialists and patients a part of his professional mission.